Web based Drug Database (1.07 Linux)

MEFENAMIC ACID

Names
Common Name	MEFENAMIC ACID
Other Name	MEFENAMIC ACID
Pharmacological Group	NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
Chemical Name	N-(2,3-Xylyl)anthranilic acid
Chemical Group

Attributes

Indications	Contraindications	Prescriber Cautions	Patient Cautions
Toxicity	Side Effects	Liver Disease	Renal Failure
Pregnancy	Lactation	Pharmacological Actions	Diagnostic Procedures
Drugs	Interactions

Indications

Toothache
Headache
Pain
Gout
Dysmenorrhoea
Menorrhagia
Rheumatoid arthritis
Juvenile rheumatoid arthritis - Still's disease
Musculoskeletal pain
Postoperative pain
Paediatric use

Contraindications

Asthma
Peptic ulcer
Analgesic allergy
Disorders of porphyrin metabolism
Chronic asthmatic bronchitis
Peptic ulcer of oesophagus
Gastric ulcer
Duodenal ulcer
Peptic ulcer - (PU) site unspecified
Gastrojejunal ulcer
Gastritis and duodenitis
Adverse reaction to antirheumatics
Adverse reaction to mefenamic acid
Airways obstruction reversible
Mefenamic acid poisoning
Non-steroidal anti-inflammatory drugs contraindicated

Prescriber Cautions

Consult current official advice regarding MEFENAMIC ACID
Regular haematological examination advised during prolonged treatment with MEFENAMIC ACID

Patient Cautions

See information on products containing MEFENAMIC ACID for specific advice for patients

Toxicity

- None Listed -

Side Effects

Abdominal pain - Common
Black faeces - Common
Constipation - Common
Dyspepsia - Common
Excessive flatulence - Common
Haematemesis - Common
Nausea - Common
Oral aphthae - Common
Vomiting - Common
Acute gastritis - Uncommon
Acute glomerulonephritis - Uncommon
Blood in urine - haematuria - Uncommon
Diarrhoea - Uncommon
Enteritis/colitis - Uncommon
Idiopathic proctocolitis - Uncommon
Interstitial nephritis - Uncommon
Peptic ulcer symptoms - Uncommon
Perforation of intestine - Uncommon
Proteinuria - Uncommon
Renal function tests abnormal - Uncommon
Thrombocytopenia - Uncommon
Agranulocytosis - Rare
Aplastic anaemia - Rare
Eosinophilia - Rare
Glucose-galactose intolerance - Rare
Hypotension - Rare
Nephrotic syndrome - Rare
Neutropenia - Rare
Palpitations - Rare
Pancytopenia - Rare
Photosensitiveness - Rare
Acute hepatitis
Acute myocardial infarction
Acute pancreatitis
Acute renal failure
Allergic purpura
Anaemia
Angioneurotic oedema
Appetite loss - anorexia
Blurred Vision
Bone marrow suppression
Bronchospasm
Bullous eruption
Colour blindness
Confusion
Convulsions
Defibrination syndrome
Depression
Dizziness
Drowsiness
Dyspnoea
Ear Pain
Erythema multiforme
Excessive sweating
Exfoliative dermatitis
Facial swelling
Fatigue/asthenia
Haematocrit - PCV - low
Hallucinations
Headache
Heart failure
Hepatorenal syndrome
Hypertension
Hyposmolality/hyponatraemia
Hypothermia
Insomnia
Intracerebral haemorrhage
Itching
Jaundice
Laryngeal oedema
Leucopenia
Liver function tests abnormal
Malaise/lethargy
Meningitis - aseptic
Multiple organ failure
Nervousness
Oedema
Optic neuritis
Pancreatic steatorrhoea
Paraesthesia
Pyrexia
Rash
Stevens-Johnson syndrome
Tinnitus
Toxic epidermal necrolysis
Visual symptoms

Liver Disease

Avoid MEFENAMIC ACID in severe liver disease
MEFENAMIC ACID causes sodium and water retention in liver disease
MEFENAMIC ACID - increased risk of gastrointestinal bleeding in liver disease

Renal Failure

Avoid MEFENAMIC ACID if possible in mild renal failure
Manufacturer advises reduce dose of MEFENAMIC ACID in renal failure
MEFENAMIC ACID - reduces renal function in renal failure
MEFENAMIC ACID - sodium and water retention in renal failure

Pregnancy

With regular doses of MEFENAMIC ACID - increased risk of closure of fetal ductus arteriosus in utero & possible persistent pulmonary hypertension of the newborn
Delayed onset & increased duration of labour with increased blood loss
Avoid MEFENAMIC ACID in the 1st TRIMESTER of pregnancy
Avoid MEFENAMIC ACID in the 3rd TRIMESTER of pregnancy
Manufacturer advises toxicity of MEFENAMIC ACID in pregnancy in animal studies

Lactation

Although MEFENAMIC ACID not known to be harmful in breast feeding some manufacturers advise avoid
Amount of MEFENAMIC ACID in breast milk too small to be harmful

Pharmacological Actions

ANALGESIC effect
ANTIINFLAMMATORY effect
ANTIPYRETIC effect
CYCLOOXYGENASE INHIBITOR effect

Diagnostic Procedures

Urine bilirubin high

Drugs containing MEFENAMIC ACID

MEFENAMIC ACID 250mg capsules
PONSTAN 250mg capsules
PONSTAN FORTE 500mg tablets
MEFENAMIC ACID 500mg tablets
MEFENAMIC ACID 50mg/5mL susp
Mefena susp 50mg/5ml 125ml Es
Mefenamic acid 250mg/5ml susp
Mefenamic acid 500mg/5ml susp

Interacting Ingredients

ACECLOFENAC
Likely interaction of ACECLOFENAC increasing the GASTRIC IRRITANT effect of MEFENAMIC ACID. Moderate risk. May need to avoid combination
ACEMETACIN
Likely interaction of MEFENAMIC ACID increasing the GASTRIC IRRITANT effect of ACEMETACIN. Moderate risk. May need to avoid combination
ALOXIPRIN
Likely interaction of MEFENAMIC ACID increasing the GASTRIC IRRITANT effect of ALOXIPRIN. Moderate risk. May need to avoid combination
ALUMINIUM HYDROXIDE
Likely interaction of ALUMINIUM HYDROXIDE reducing the GASTRO-INTESTINAL ABSORPTION of MEFENAMIC ACID. Usually no risk. Usually no action necessary
ALUMINIUM HYDROXIDE MAGNESIUM CARBONATE CODRt
Likely interaction of ALUMINIUM HYDROXIDE MAGNESIUM CARBONATE CODRt reducing the GASTRO-INTESTINAL ABSORPTION of MEFENAMIC ACID. Usually no risk. Usually no action necessary
ALUMINIUM HYDROXIDE [EXCIPIENT]
Likely interaction of ALUMINIUM HYDROXIDE [EXCIPIENT] reducing the GASTRO-INTESTINAL ABSORPTION of MEFENAMIC ACID. Usually no risk. Usually no action necessary
AMINOPHYLLINE
Infrequent reports of MEFENAMIC ACID reducing the BRONCHODILATOR effect of AMINOPHYLLINE. Moderate risk. Avoid
ASPIRIN [RECTUM]
Likely interaction of MEFENAMIC ACID increasing the GASTRIC IRRITANT effect of ASPIRIN [RECTUM]. Moderate risk. May need to avoid combination
BAMBUTEROL HYDROCHLORIDE
Infrequent reports of MEFENAMIC ACID reducing the BRONCHODILATOR effect of BAMBUTEROL HYDROCHLORIDE. Moderate risk. Avoid
BISMUTH CHELATE
Likely interaction of MEFENAMIC ACID reducing the ULCER HEALING effect of BISMUTH CHELATE. Moderate risk. Avoid
BUDESONIDE [GASTROINTESTINAL]
Likely interaction of BUDESONIDE [GASTROINTESTINAL] increasing the GASTRIC IRRITANT effect of MEFENAMIC ACID. Moderate risk. Monitor
BUFYLLINE
Infrequent reports of MEFENAMIC ACID reducing the BRONCHODILATOR effect of BUFYLLINE. Moderate risk. Avoid
CANDESARTAN CILEXETIL
Likely interaction of MEFENAMIC ACID increasing the NEPHROTOXICITY of CANDESARTAN CILEXETIL. Potential risk. Monitor
CARBENOXOLONE
Likely interaction of MEFENAMIC ACID reducing the ULCER HEALING effect of CARBENOXOLONE. Moderate risk. Avoid
CHOLINE THEOPHYLLINATE
Infrequent reports of MEFENAMIC ACID reducing the BRONCHODILATOR effect of CHOLINE THEOPHYLLINATE. Moderate risk. Avoid
CIMETIDINE
Likely interaction of MEFENAMIC ACID reducing the ULCER HEALING effect of CIMETIDINE. Moderate risk. Avoid
CLOPIDOGREL
Theoretical potential for MEFENAMIC ACID increasing the PLATELET ANTAGONIST effect of CLOPIDOGREL. Moderate risk. May need to avoid combination
CROMOGLICATE [INHALED]
Infrequent reports of MEFENAMIC ACID reducing the BRONCHODILATOR effect of CROMOGLICATE [INHALED]. Moderate risk. Avoid
DEGLYCYRRHIZINISED LIQUORICE
Likely interaction of MEFENAMIC ACID reducing the ULCER HEALING effect of DEGLYCYRRHIZINISED LIQUORICE. Moderate risk. Avoid
DEXAMETHASONE [PARENTERAL]
Likely interaction of DEXAMETHASONE [PARENTERAL] increasing the GASTRIC IRRITANT effect of MEFENAMIC ACID. Moderate risk. Monitor
DEXIBUPROFEN
Likely interaction of MEFENAMIC ACID increasing the GASTRIC IRRITANT effect of DEXIBUPROFEN. Moderate risk. May need to avoid combination
DEXKETOPROFEN
Likely interaction of MEFENAMIC ACID increasing the GASTRIC IRRITANT effect of DEXKETOPROFEN. Moderate risk. May need to avoid combination
DICLOFENAC POTASSIUM
Likely interaction of MEFENAMIC ACID increasing the GASTRIC IRRITANT effect of DICLOFENAC POTASSIUM. Moderate risk. May need to avoid combination
DICLOFENAC SODIUM [PARENTERAL]
Likely interaction of MEFENAMIC ACID increasing the GASTRIC IRRITANT effect of DICLOFENAC SODIUM [PARENTERAL]. Moderate risk. May need to avoid combination
DICLOFENAC SODIUM [RECTUM]
Likely interaction of MEFENAMIC ACID increasing the GASTRIC IRRITANT effect of DICLOFENAC SODIUM [RECTUM]. Moderate risk. May need to avoid combination
DIPROPHYLLINE
Infrequent reports of MEFENAMIC ACID reducing the BRONCHODILATOR effect of DIPROPHYLLINE. Moderate risk. Avoid
EPHEDRINE HYDROCHLORIDE
Infrequent reports of MEFENAMIC ACID reducing the BRONCHODILATOR effect of EPHEDRINE HYDROCHLORIDE. Moderate risk. Avoid
EPROSARTAN
Likely interaction of MEFENAMIC ACID increasing the NEPHROTOXICITY of EPROSARTAN. Potential risk. Monitor
ESOMEPRAZOLE
Likely interaction of MEFENAMIC ACID reducing the ULCER HEALING effect of ESOMEPRAZOLE. Moderate risk. Avoid
FAMOTIDINE
Likely interaction of MEFENAMIC ACID reducing the ULCER HEALING effect of FAMOTIDINE. Moderate risk. Avoid
FENOTEROL HYDROBROMIDE
Infrequent reports of MEFENAMIC ACID reducing the BRONCHODILATOR effect of FENOTEROL HYDROBROMIDE. Moderate risk. Avoid
FLURBIPROFEN [RECTUM]
Likely interaction of FLURBIPROFEN [RECTUM] increasing the GASTRIC IRRITANT effect of MEFENAMIC ACID. Moderate risk. May need to avoid combination
FONDAPARINUX SODIUM
Likely interaction of MEFENAMIC ACID increasing the ANTICOAGULANT effect of FONDAPARINUX SODIUM. Moderate risk. May need to avoid combination
FORMOTEROL
Infrequent reports of MEFENAMIC ACID reducing the BRONCHODILATOR effect of FORMOTEROL. Moderate risk. Avoid
GEL

AZAPROPAZONE
Likely interaction of AZAPROPAZONE increasing the GASTRIC IRRITANT effect of MEFENAMIC ACID. Moderate risk. May need to avoid combination
BECLOMETASONE [INHALED]
Infrequent reports of MEFENAMIC ACID reducing the BRONCHODILATOR effect of BECLOMETASONE [INHALED]. Moderate risk. Avoid
BENORILATE
Likely interaction of MEFENAMIC ACID increasing the GASTRIC IRRITANT effect of BENORILATE. Moderate risk. May need to avoid combination
BETAMETHASONE
Likely interaction of BETAMETHASONE increasing the GASTRIC IRRITANT effect of MEFENAMIC ACID. Moderate risk. Monitor
BETAMETHASONE [INHALED]
Infrequent reports of MEFENAMIC ACID reducing the BRONCHODILATOR effect of BETAMETHASONE [INHALED]. Moderate risk. Avoid
BUDESONIDE [INHALED]
Infrequent reports of MEFENAMIC ACID reducing the BRONCHODILATOR effect of BUDESONIDE [INHALED]. Moderate risk. Avoid
CHOLINE MAGNESIUM TRISALICYLATE
Likely interaction of CHOLINE MAGNESIUM TRISALICYLATE increasing the GASTRIC IRRITANT effect of MEFENAMIC ACID. Moderate risk. May need to avoid combination
CICLOSPORIN
Infrequent reports of MEFENAMIC ACID increasing the NEPHROTOXICITY of CICLOSPORIN. Moderate risk. Monitor
CORTISONE ACETATE
Likely interaction of CORTISONE ACETATE increasing the GASTRIC IRRITANT effect of MEFENAMIC ACID. Moderate risk. Monitor
DANAPAROID SODIUM
Theoretical potential for MEFENAMIC ACID increasing the ANTICOAGULANT effect of DANAPAROID SODIUM. Moderate risk. May need to avoid combination
DEXAMETHASONE [ORAL]
Likely interaction of DEXAMETHASONE [ORAL] increasing the GASTRIC IRRITANT effect of MEFENAMIC ACID. Moderate risk. Monitor
DICLOFENAC SODIUM [ORAL]
Likely interaction of MEFENAMIC ACID increasing the GASTRIC IRRITANT effect of DICLOFENAC SODIUM [ORAL]. Moderate risk. May need to avoid combination
DIFLUNISAL
Likely interaction of DIFLUNISAL increasing the GASTRIC IRRITANT effect of MEFENAMIC ACID. Moderate risk. May need to avoid combination
ENOXAPARIN
Likely interaction of MEFENAMIC ACID increasing the ANTICOAGULANT effect of ENOXAPARIN. Moderate risk. May need to avoid combination
ETODOLAC
Likely interaction of MEFENAMIC ACID increasing the GASTRIC IRRITANT effect of ETODOLAC. Moderate risk. May need to avoid combination
FENBUFEN
Likely interaction of FENBUFEN increasing the GASTRIC IRRITANT effect of MEFENAMIC ACID. Moderate risk. May need to avoid combination
FENOPROFEN
Likely interaction of FENOPROFEN increasing the GASTRIC IRRITANT effect of MEFENAMIC ACID. Moderate risk. May need to avoid combination
FLUDROCORTISONE ACETATE
Likely interaction of FLUDROCORTISONE ACETATE increasing the GASTRIC IRRITANT effect of MEFENAMIC ACID. Moderate risk. Monitor
FLURBIPROFEN
Likely interaction of FLURBIPROFEN increasing the GASTRIC IRRITANT effect of MEFENAMIC ACID. Moderate risk. May need to avoid combination
FLUTICASONE [INHALED]
Infrequent reports of MEFENAMIC ACID reducing the BRONCHODILATOR effect of FLUTICASONE [INHALED]. Moderate risk. Avoid
HYDROCORTISONE
Likely interaction of HYDROCORTISONE increasing the GASTRIC IRRITANT effect of MEFENAMIC ACID. Moderate risk. Monitor
HYDROCORTISONE SODIUM PHOSPHATE
Likely interaction of HYDROCORTISONE SODIUM PHOSPHATE increasing the GASTRIC IRRITANT effect of MEFENAMIC ACID. Moderate risk. Monitor
HYDROCORTISONE SODIUM SUCCINATE
Likely interaction of HYDROCORTISONE SODIUM SUCCINATE increasing the GASTRIC IRRITANT effect of MEFENAMIC ACID. Moderate risk. Monitor
IBUPROFEN
Likely interaction of MEFENAMIC ACID increasing the GASTRIC IRRITANT effect of IBUPROFEN. Moderate risk. May need to avoid combination
IBUPROFEN LYSINE
Likely interaction of MEFENAMIC ACID increasing the GASTRIC IRRITANT effect of IBUPROFEN LYSINE. Moderate risk. May need to avoid combination
INDACATEROL
Infrequent reports of MEFENAMIC ACID reducing the BRONCHODILATOR effect of INDACATEROL. Moderate risk. Avoid
INDOMETACIN
Likely interaction of INDOMETACIN increasing the GASTRIC IRRITANT effect of MEFENAMIC ACID. Moderate risk. May need to avoid combination
INDOMETACIN [RECTUM]
Likely interaction of INDOMETACIN [RECTUM] increasing the GASTRIC IRRITANT effect of MEFENAMIC ACID. Moderate risk. May need to avoid combination
IRBESARTAN
Likely interaction of MEFENAMIC ACID increasing the NEPHROTOXICITY of IRBESARTAN. Potential risk. Monitor
ISOETARINE HYDROCHLORIDE
Infrequent reports of MEFENAMIC ACID reducing the BRONCHODILATOR effect of ISOETARINE HYDROCHLORIDE. Moderate risk. Avoid
ISOPRENALINE HYDROCHLORIDE
Infrequent reports of MEFENAMIC ACID reducing the BRONCHODILATOR effect of ISOPRENALINE HYDROCHLORIDE. Moderate risk. Avoid
ISOPRENALINE SULPHATE
Infrequent reports of MEFENAMIC ACID reducing the BRONCHODILATOR effect of ISOPRENALINE SULPHATE. Moderate risk. Avoid
KETOPROFEN
Likely interaction of MEFENAMIC ACID increasing the GASTRIC IRRITANT effect of KETOPROFEN. Moderate risk. May need to avoid combination
KETOPROFEN [RECTUM]
Likely interaction of MEFENAMIC ACID increasing the GASTRIC IRRITANT effect of KETOPROFEN [RECTUM]. Moderate risk. May need to avoid combination
KETOROLAC TROMETAMOL
Likely interaction of MEFENAMIC ACID increasing the PLATELET ANTAGONIST effect of KETOROLAC TROMETAMOL. High risk. Avoid
KETOTIFEN
Infrequent reports of MEFENAMIC ACID reducing the BRONCHODILATOR effect of KETOTIFEN. Moderate risk. Avoid
LANSOPRAZOLE
Likely interaction of MEFENAMIC ACID reducing the ULCER HEALING effect of LANSOPRAZOLE. Moderate risk. Avoid
LITHIUM CARBONATE
Infrequent reports of MEFENAMIC ACID increasing the CNS TOXICITY of LITHIUM CARBONATE. Moderate risk. Monitor
LITHIUM CHLORIDE [PARENTERAL]
Infrequent reports of MEFENAMIC ACID increasing the CNS TOXICITY of LITHIUM CHLORIDE [PARENTERAL]. Moderate risk. Monitor
LITHIUM CITRATE
Infrequent reports of MEFENAMIC ACID increasing the CNS TOXICITY of LITHIUM CITRATE. Moderate risk. Monitor
LOSARTAN POTASSIUM
Likely interaction of MEFENAMIC ACID increasing the NEPHROTOXICITY of LOSARTAN POTASSIUM. Potential risk. Monitor
LYSINE ASPIRIN
Likely interaction of MEFENAMIC ACID increasing the GASTRIC IRRITANT effect of LYSINE ASPIRIN. Moderate risk. May need to avoid combination
MELOXICAM
Likely interaction of MELOXICAM increasing the GASTRIC IRRITANT effect of MEFENAMIC ACID. Moderate risk. May need to avoid combination
MELOXICAM [RECTUM]
Likely interaction of MELOXICAM [RECTUM] increasing the GASTRIC IRRITANT effect of MEFENAMIC ACID. Moderate risk. May need to avoid combination
MESALAZINE
Theoretical potential for MEFENAMIC ACID increasing the NEPHROTOXICITY of MESALAZINE. Potential risk. May need to avoid combination
METHYLEPHEDRINE
Infrequent reports of MEFENAMIC ACID reducing the BRONCHODILATOR effect of METHYLEPHEDRINE. Moderate risk. Avoid
METHYLPREDNISOLONE
Likely interaction of METHYLPREDNISOLONE increasing the GASTRIC IRRITANT effect of MEFENAMIC ACID. Moderate risk. Monitor
MIFEPRISTONE
Theoretical potential for MEFENAMIC ACID increasing the PROSTANERGIC effect of MIFEPRISTONE. Potential risk. Avoid
MONTELUKAST
Infrequent reports of MEFENAMIC ACID reducing the BRONCHODILATOR effect of MONTELUKAST. Moderate risk. Avoid
NABUMETONE
Likely interaction of NABUMETONE increasing the GASTRIC IRRITANT effect of MEFENAMIC ACID. Moderate risk. May need to avoid combination
NAPROXEN
Likely interaction of MEFENAMIC ACID increasing the GASTRIC IRRITANT effect of NAPROXEN. Moderate risk. May need to avoid combination
NAPROXEN SODIUM
Likely interaction of MEFENAMIC ACID increasing the GASTRIC IRRITANT effect of NAPROXEN SODIUM. Moderate risk. May need to avoid combination
NAPROXEN [RECTUM]
Likely interaction of MEFENAMIC ACID increasing the GASTRIC IRRITANT effect of NAPROXEN [RECTUM]. Moderate risk. May need to avoid combination
NEDOCROMIL SODIUM
Infrequent reports of MEFENAMIC ACID reducing the BRONCHODILATOR effect of NEDOCROMIL SODIUM. Moderate risk. Avoid
NIZATIDINE
Likely interaction of MEFENAMIC ACID reducing the ULCER HEALING effect of NIZATIDINE. Moderate risk. Avoid
OLMESARTAN MEDOXOMIL
Likely interaction of MEFENAMIC ACID increasing the NEPHROTOXICITY of OLMESARTAN MEDOXOMIL. Potential risk. Monitor
OMEPRAZOLE [ORAL]
Likely interaction of MEFENAMIC ACID reducing the ULCER HEALING effect of OMEPRAZOLE [ORAL]. Moderate risk. Avoid
OMEPRAZOLE [PARENTERAL]
Likely interaction of MEFENAMIC ACID reducing the ULCER HEALING effect of OMEPRAZOLE [PARENTERAL]. Moderate risk. Avoid
ORCIPRENALINE
Infrequent reports of MEFENAMIC ACID reducing the BRONCHODILATOR effect of ORCIPRENALINE. Moderate risk. Avoid
ORCIPRENALINE [INHALED]
Infrequent reports of MEFENAMIC ACID reducing the BRONCHODILATOR effect of ORCIPRENALINE [INHALED]. Moderate risk. Avoid
PANTOPRAZOLE
Likely interaction of MEFENAMIC ACID reducing the ULCER HEALING effect of PANTOPRAZOLE. Moderate risk. Avoid
PHENYLBUTAZONE
Likely interaction of MEFENAMIC ACID increasing the GASTRIC IRRITANT effect of PHENYLBUTAZONE. Moderate risk. May need to avoid combination
PIRBUTEROL
Infrequent reports of MEFENAMIC ACID reducing the BRONCHODILATOR effect of PIRBUTEROL. Moderate risk. Avoid
PIROXICAM
Likely interaction of MEFENAMIC ACID increasing the GASTRIC IRRITANT effect of PIROXICAM. Moderate risk. May need to avoid combination
PIROXICAM [RECTUM]
Likely interaction of MEFENAMIC ACID increasing the GASTRIC IRRITANT effect of PIROXICAM [RECTUM]. Moderate risk. May need to avoid combination
PIROXICAM-BETADEX
Likely interaction of MEFENAMIC ACID increasing the GASTRIC IRRITANT effect of PIROXICAM-BETADEX. Moderate risk. May need to avoid combination
PREDNISOLONE
Likely interaction of PREDNISOLONE increasing the GASTRIC IRRITANT effect of MEFENAMIC ACID. Moderate risk. Monitor
PREDNISOLONE ACETATE
Likely interaction of PREDNISOLONE ACETATE increasing the GASTRIC IRRITANT effect of MEFENAMIC ACID. Moderate risk. Monitor
PREDNISOLONE SODIUM PHOSPHATE
Likely interaction of PREDNISOLONE SODIUM PHOSPHATE increasing the GASTRIC IRRITANT effect of MEFENAMIC ACID. Moderate risk. Monitor
PREDNISONE
Likely interaction of PREDNISONE increasing the GASTRIC IRRITANT effect of MEFENAMIC ACID. Moderate risk. Monitor
RABEPRAZOLE
Likely interaction of MEFENAMIC ACID reducing the ULCER HEALING effect of RABEPRAZOLE. Moderate risk. Avoid
RANITIDINE
Likely interaction of MEFENAMIC ACID reducing the ULCER HEALING effect of RANITIDINE. Moderate risk. Avoid
RANITIDINE BISMUTH CITRATE
Likely interaction of MEFENAMIC ACID reducing the ULCER HEALING effect of RANITIDINE BISMUTH CITRATE. Moderate risk. Avoid
REPROTEROL HYDROCHLORIDE
Infrequent reports of MEFENAMIC ACID reducing the BRONCHODILATOR effect of REPROTEROL HYDROCHLORIDE. Moderate risk. Avoid
RIMITEROL HYDROBROMIDE
Infrequent reports of MEFENAMIC ACID reducing the BRONCHODILATOR effect of RIMITEROL HYDROBROMIDE. Moderate risk. Avoid
RITODRINE HYDROCHLORIDE
Infrequent reports of MEFENAMIC ACID reducing the BRONCHODILATOR effect of RITODRINE HYDROCHLORIDE. Moderate risk. Avoid
SALBUTAMOL
Infrequent reports of MEFENAMIC ACID reducing the BRONCHODILATOR effect of SALBUTAMOL. Moderate risk. Avoid
SALBUTAMOL [INHALED]
Infrequent reports of MEFENAMIC ACID reducing the BRONCHODILATOR effect of SALBUTAMOL [INHALED]. Moderate risk. Avoid
SALICYLAMIDE
Likely interaction of SALICYLAMIDE increasing the GASTRIC IRRITANT effect of MEFENAMIC ACID. Moderate risk. May need to avoid combination
SALIX
Likely interaction of SALIX increasing the GASTRIC IRRITANT effect of MEFENAMIC ACID. Moderate risk. May need to avoid combination
SALMETEROL XINAFOATE
Infrequent reports of MEFENAMIC ACID reducing the BRONCHODILATOR effect of SALMETEROL XINAFOATE. Moderate risk. Avoid
SALSALATE
Likely interaction of MEFENAMIC ACID increasing the GASTRIC IRRITANT effect of SALSALATE. Moderate risk. May need to avoid combination
SODIUM SALICYLATE
Likely interaction of SODIUM SALICYLATE increasing the GASTRIC IRRITANT effect of MEFENAMIC ACID. Moderate risk. May need to avoid combination
SUCRALFATE
Likely interaction of MEFENAMIC ACID reducing the ULCER HEALING effect of SUCRALFATE. Moderate risk. Avoid
SULINDAC
Likely interaction of SULINDAC increasing the GASTRIC IRRITANT effect of MEFENAMIC ACID. Moderate risk. May need to avoid combination
TELMISARTAN
Likely interaction of MEFENAMIC ACID increasing the NEPHROTOXICITY of TELMISARTAN. Potential risk. Monitor
TENOXICAM
Likely interaction of MEFENAMIC ACID increasing the GASTRIC IRRITANT effect of TENOXICAM. Moderate risk. May need to avoid combination
TERBUTALINE
Infrequent reports of MEFENAMIC ACID reducing the BRONCHODILATOR effect of TERBUTALINE. Moderate risk. Avoid
TERBUTALINE [INHALED]
Infrequent reports of MEFENAMIC ACID reducing the BRONCHODILATOR effect of TERBUTALINE [INHALED]. Moderate risk. Avoid
THEOPHYLLINE
Infrequent reports of MEFENAMIC ACID reducing the BRONCHODILATOR effect of THEOPHYLLINE. Moderate risk. Avoid
TIAPROFENIC ACID
Likely interaction of TIAPROFENIC ACID increasing the GASTRIC IRRITANT effect of MEFENAMIC ACID. Moderate risk. May need to avoid combination
TINZAPARIN SODIUM
Likely interaction of MEFENAMIC ACID increasing the ANTICOAGULANT effect of TINZAPARIN SODIUM. Moderate risk. May need to avoid combination
TOLFENAMIC ACID
Likely interaction of TOLFENAMIC ACID increasing the GASTRIC IRRITANT effect of MEFENAMIC ACID. Moderate risk. May need to avoid combination
TOLMETIN
Likely interaction of TOLMETIN increasing the GASTRIC IRRITANT effect of MEFENAMIC ACID. Moderate risk. May need to avoid combination
TRIAMCINOLONE ACETONIDE
Likely interaction of TRIAMCINOLONE ACETONIDE increasing the GASTRIC IRRITANT effect of MEFENAMIC ACID. Moderate risk. Monitor
TULOBUTEROL HYDROCHLORIDE
Infrequent reports of MEFENAMIC ACID reducing the BRONCHODILATOR effect of TULOBUTEROL HYDROCHLORIDE. Moderate risk. Avoid
VALSARTAN
Likely interaction of MEFENAMIC ACID increasing the NEPHROTOXICITY of VALSARTAN. Potential risk. Monitor
WARFARIN SODIUM
Theoretical potential for MEFENAMIC ACID increasing the ANTICOAGULANT effect of WARFARIN SODIUM. Moderate risk. Monitor
ZAFIRLUKAST
Infrequent reports of MEFENAMIC ACID reducing the BRONCHODILATOR effect of ZAFIRLUKAST. Moderate risk. Avoid